NDC product
Pryidostigmine Bromide
NDC 16571-833 · Rising Pharma Holdings, Inc.
Key facts
| Product NDC | 16571-833 |
|---|---|
| Proprietary name | Pryidostigmine Bromide |
| Nonproprietary name | Pyridostigmine Bromide |
| Substances | PYRIDOSTIGMINE BROMIDE |
| Dosage form | SOLUTION |
| Route | ORAL |
| Labeler | Rising Pharma Holdings, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA208797 |
| Pharmacologic classes | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| Marketing start | Sep 15, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: